The invention relates to the use of a compound(s) selected from isoniazid and isoniazid analogs of formula Ia, wherein R is &mdash；C(O)NHNH2, &mdash；C(O)NHNHC1-6 alkyl, &mdash；C(O)NHN&boxH；C1-6 alkenyl, &mdash；C(O)NHNHC2-6 alkenyl, &mdash；C(O)NHC1-6 alkyl, &mdash；C(O)NHC2-6 alkenyl, &mdash；C(O)NHNHC(O)C1-6alkyl, &mdash；NHC(O)C1-6 alkyl, &mdash；NHC(O)C1-6 alkenyl, &mdash；NHC(O)NH2, &mdash；NHC(O)NHC1-6alkyl, &mdash；NHC(O)NHC2-6 alkenyl, or &mdash；COOH, and wherein formula (Ia) optionally is further substituted with one or more substituents； or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the preparation of a pharmaceutical composition for treating a condition selected from the group consisting of cutaneous lesions, wounds, ulcers and infarcts in a tissue area with compromised vascularisation, in an animal, such as a human subject. The compound is preferably isoniazid, or pharmaceutical acceptable salts, solvates or prodrugs thereof, and the conditions to be treated is for example selected from the group consisting of pressure ulcers, diabetic ulcers, arterial ulcers and anastomotic ulcers. The invention furthermore relates to a method of treating a condition selected from wounds, ulcers or infarcts in a tissue area with compromised vascularisation in an animal, such as a human subject.
